Table 1.

Clinical characteristics of patient cohort with relapsed/refractory CLL treated with venetoclax (n = 89)

Clinical characteristic	Cohort (n = 89)
Median age at venetoclax initiation, years (range)	67 (45-87)
Male:Female	71:18
Median number of prior therapies (range)	3 (0-12)
Prior fludarabine-combination therapy exposure	72 (81%)
Del(17p) and/or TP53 mutation prior to venetoclax initiation (n/N, %)	46/81 (57%)
Median duration on venetoclax, months (range)	29 (1-98+)
Median survivor follow-up from venetoclax initiation, months (range)	75 (21-98+)